Sign up to save your podcasts
Or
Share CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome
In the first part of the podcast, Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. In the second segment, Dr. Pearce Korb discusses the long-term outcomes of osmotic demyelination syndrome in an updated cohort with Dr. Whitney Fitts.
View all episodes
By American Academy of Neurology
4.7
272272 ratings
In the first part of the podcast, Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. In the second segment, Dr. Pearce Korb discusses the long-term outcomes of osmotic demyelination syndrome in an updated cohort with Dr. Whitney Fitts.
More shows like Neurology® Podcast
View all
JAMA Editors' Summary
130 Listeners
NEJM This Week
325 Listeners
Practical Neurology Podcast
45 Listeners
JAMA Clinical Reviews
492 Listeners
The Curbsiders Internal Medicine Podcast
3,320 Listeners
JAMA Neurology Author Interviews
14 Listeners
Core IM | Internal Medicine Podcast
1,086 Listeners
Neurology Today in 5
21 Listeners
Annals On Call Podcast
185 Listeners
The Clinical Problem Solvers
515 Listeners
Neurology Minute
132 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
348 Listeners
Neurology Exam Prep Podcast
182 Listeners
The Curious Clinicians
366 Listeners
Continuum Audio
77 Listeners